Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 6144.

https://doi.org/10.1182/blood-2024-209459

Published: 2024

Journal Articles

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Chunmei Yang, Liping Mao, Juying Wei, Wanzhuo Xie, Xingnong Ye, Min Yang, Jian Huang, De Zhou, Liya Ma, Yinjun Lou, Huafeng Wang, Jie Jin, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6518.

https://doi.org/10.1182/blood-2024-202298

Published: 2024

Journal Articles

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Haiyan Zhang, Xiang Zhang, Jinghan Wang, Xuewu Zhang, Yunfei Lv, Yanan Zhu, Juying Wei, Min Yang, Gaixiang Xu, Xingnong Ye, Yinjun Lou, Chunmei Yang, Haitao Meng, Wanzhuo Xie, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6468.

https://doi.org/10.1182/blood-2024-205687

Published: 2024

Journal Articles

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

Xuewu Zhang, Yanan Zhu, Xiang Zhang, Xingnong Ye, Gaixiang Xu, Liya Ma, Yanling Ren, Liping Mao, Min Yang, Chunmei Yang, Juying Wei, Yinjun Lou, Wenyuan Mai, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6280.

https://doi.org/10.1182/blood-2024-204442

Published: 2024

Journal Articles

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Yiyi Yao, Yile Zhou, Nanfang Zhuo, Wanzhuo Xie, Haitao Meng, Yinjun Lou, Liping Mao, Hongyan Tong, Jiejing Qian, Min Yang, Wenjuan Yu, De Zhou, Jian Huang, Jie Jin, Huafeng Wang

Blood (2024) 144 (Supplement 1): 7485.

https://doi.org/10.1182/blood-2024-204411

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome in Combination with Cytarabine and Venetoclax (MAV) Regimen in Relapsed or Refractory Acute Myeloid Leukemia

Huafeng Wang, Yile Zhou, Min Yang, De Zhou, Jian Huang, Liping Mao, Yinjun Lou, Wanzhuo Xie, Jie Jin

Blood (2024) 144 (Supplement 1): 6076.

https://doi.org/10.1182/blood-2024-210439

Published: 2024

Journal Articles

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Blood (2024) 144 (Supplement 1): 836.

https://doi.org/10.1182/blood-2024-208355

Published: 2024

Journal Articles

Clinical Characteristics and Prognostic Analysis of Patients with Aggressive Mantle Cell Lymphoma：a Single-Center Real-World Study in China

Ying Huang, Yanan Zhu, Xiang Zhang, Xuewu Zhang, Juying Wei, Xingnong Ye, Yinjun Lou, Min Yang, Chunmei Yang, Wanzhuo Xie, Haitao Meng, Jie Jin, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6306.

https://doi.org/10.1182/blood-2024-205842

Published: 2024

Journal Articles

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

Xuewu Zhang, Haitao Meng, Gaixiang Xu, Min Yang, Wanzhuo Xie, Juying Wei, Liya Ma, Xingnong Ye, Liping Mao, Wenyuan Mai, Chunmei Yang, Yanling Ren, Hongyan Tong, Yanan Zhu, Xiang Zhang, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6772.

https://doi.org/10.1182/blood-2024-203639

Published: 2024

Journal Articles

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Jianai Sun, Yi Xu, Huafeng Wang, Xiaolong Zheng, Wenjuan Yu, De Zhou, Chunmei Yang, Xinping Zhou, Liping Mao, Haitao Meng, Liangshun You, Min Yang, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2024) 144 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2024-197872

Published: 2024

Journal Articles

Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma

Chunmei Yang, Juying Wei, Ying Lu, Liping Mao, Min Yang, Huafeng Wang, De Zhou, Hongyan Tong, Jie Jin, Wen-Juan Yu

Blood (2024) 144 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2024-203722

Published: 2024

Journal Articles

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

Blood (2023) 142 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2023-184470

Published: 2023

Journal Articles

High Grade B-Cell Lymphoma with 11q Aberration Is Not a Rare Event in HIV-Associated Lymphoma

Amy Chadburn, Paul Rubinstein, Ethel Cesarman, Swarna Gogineni, MIn Yang, Maneeza Bilal, Nadine Demko, Ivo N. Sah Bander, Chandler Sy, Victoria Alagiozian-Angelova, Liming Bao

Blood (2023) 142 (Supplement 1): 3121.

https://doi.org/10.1182/blood-2023-190635

Published: 2023

Journal Articles

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Blood (2023) 142 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2023-182817

Published: 2023

Journal Articles

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6001.

https://doi.org/10.1182/blood-2023-186048

Published: 2023

Journal Articles

Venetoclax Plus ‘2 + 5‘ Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukaemia: A Single-Centre Retrospective Analysis

Jiajia Pan, Huafeng Wang, Liping Mao, Yinjun Lou, Yanling Ren, Xingnong Ye, Honghu Zhu, Min Yang, Jiejing Qian, Jie Jin

Blood (2023) 142 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2023-180770

Published: 2023

Journal Articles

Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed

Blood (2022) 140 (Supplement 1): 2263–2264.

https://doi.org/10.1182/blood-2022-170604

Published: 2022

Journal Articles

The ZR2-Minichop Study：Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Jianai Sun, Yi Xu, Min Yang, Huafeng Wang, Wenjuan Yu, Liangshun You, Haitao Meng, Chunmei Yang, Xinping Zhou, Li Li, De Zhou, Xiujing Ye, Hong-hu Zhu, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2022) 140 (Supplement 1): 3756.

https://doi.org/10.1182/blood-2022-158723

Published: 2022

Journal Articles

Simultaneous Inhibition of SIRT3 and Cholesterol Homeostasis Targets AML Stem Cells By Perturbing Fatty Acid β-Oxidation and Inducing Lipotoxicity

Blood (2022) 140 (Supplement 1): 104–106.

https://doi.org/10.1182/blood-2022-157794

Published: 2022

Journal Articles

Clinical Features and Outcomes of Pre-Fibrotic Primary Myelofibrosis Patients with Triple-Negative, JAK2V617F and Calr Mutations

Shiwei Hu, Danhong Xiang, Min Yang, Jian Huang

Blood (2022) 140 (Supplement 1): 3957–3958.

https://doi.org/10.1182/blood-2022-165004

Published: 2022

NARROW

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Mitoxantrone Hydrochloride Liposome in Combination with Cytarabine and Venetoclax (MAV) Regimen in Relapsed or Refractory Acute Myeloid Leukemia

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Clinical Characteristics and Prognostic Analysis of Patients with Aggressive Mantle Cell Lymphoma：a Single-Center Real-World Study in China

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

High Grade B-Cell Lymphoma with 11q Aberration Is Not a Rare Event in HIV-Associated Lymphoma

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Venetoclax Plus ‘2 + 5‘ Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukaemia: A Single-Centre Retrospective Analysis

Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed

The ZR2-Minichop Study：Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Simultaneous Inhibition of SIRT3 and Cholesterol Homeostasis Targets AML Stem Cells By Perturbing Fatty Acid β-Oxidation and Inducing Lipotoxicity

Clinical Features and Outcomes of Pre-Fibrotic Primary Myelofibrosis Patients with Triple-Negative, JAK2V617F and Calr Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only